Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG

Journal of the National Cancer Institute

Volumn 105, Issue 24, 2013, Pages 1881-1890

  Pettersson, Andreas ^a,c   Lis, Rosina T ^e,f   Meisner, Allison ^a   Flavin, Richard ^f,h,i   Stack, Edward C ^e,f   Fiorentino, Michelangelo ^a,f,j   Finn, Stephen ^f,h,i   Graff, Rebecca E ^a   Penney, Kathryn L ^a,c   Rider, Jennifer R ^a,c   Nuttall, Elizabeth J ^a   Martin, Neil E ^b,f   Sesso, Howard D ^d   Pollak, Michael ^f,k   Stampfer, Meir J ^a,b,c   Kantoff, Philip W ^g   Giovannucci, Edward L ^a,b,c   Loda, Massimo ^e   Mucci, Lorelei A ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Department of Nutrition ^*  (United States)

^c CHANNING LABORATORY   (United States)

^d Division of Preventive Medicine   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Center for Molecular   (United States)

^g Lank Center for Genitourinary Oncology   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ TRINITY COLLEGE DUBLIN   (Ireland)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ERG; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER PATIENT; CANCER TISSUE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISTANT METASTASIS; FOLLOW UP; GENE OVEREXPRESSION; HAZARD RATIO; HEALTH PRACTITIONER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSURETHRAL RESECTION; VERY ELDERLY; WAIST CIRCUMFERENCE;

EID: 84891437243     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt332     Document Type: Article

References (30)

1. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4(4):486-501.
2. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9(11):1039-1047.
3. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society; 2013.
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303(3):235-241.
5. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-591.
6. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010;28(26):4058-4065.
7. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644- 648.
8. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol. 2011;29(27):3659-3668.
9. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100(11):815-825.
10. Mackintosh C, Madoz-Gurpide J, Ordonez JL, Osuna D, Herrero-Martin D. The molecular pathogenesis of Ewing's sarcoma. Cancer Biol Ther. 2010;9(9):655-667.
11. Ho AL, Schwartz GK. Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? J Clin Oncol. 2011;29(34):4581-4583.
12. Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011;35(7):1014-1020.
13. Hennekens CH, Eberlein K. A randomized trial of aspirin and beta-carotene among U.S. physicians. Prev Med. 1985;14(2):165-168.
14. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571-1578.
15. Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009;27(21):3459-3464.
16. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1(6):466-473.
17. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-4599.
18. Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:erg rearrangement, erg expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1497-1509.
19. World Health Organization. Global Database on Body Mass Index. Available at: http://apps.who.int/bmi/index.jsp?introPage=intro-3.html. Accessed November 19, 2013.
20. World Health Organization. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation, Geneva, 8-11 December 2008. Geneva, Switzerland: World Health Organization; 2011.
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
22. McKinsey EL, Parrish JK, Irwin AE, et al. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene. 2011;30(49):4910-4920.
23. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41(5):524-526.
24. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA. 2009;106(30):12465-12470.
25. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41(5):619-624.
26. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763-777.
27. Migita T, Ruiz S, Fornari A, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009;101(7):519-532.
28. Nguyen PL, Ma J, Chavarro JE, et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010;28(25):3958-3964.
29. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;26(35):5713-5720.
30. Keto CJ, Aronson WJ, Terris MK, et al. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2012;110(4):492-498.